Skip to main content
SpringerLink
Log in

Early experience with gemcitabine in solid tumours encouraging

  • New Drugs and Therapeutic
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Schellens JHM, Pronk LC, Verweij J. Emerging drug treatments for solid tumours. Drugs 1996 Jan; 51(1): 45–72

    Article  PubMed  CAS  Google Scholar 

  2. Carmichael J, Possinger K, Phillip P, et al. Advanced Breast Cancer: a phase II trial with gemcitabine. J Clin Oncol 1995; 13(11): 2731–6

    PubMed  CAS  Google Scholar 

  3. Lund B, Kristjansen PEG, Hansen HH. Clinical and preclinical activity of 2′,2′-difluorodeoxycytidine (gemcitabine). Cancer Treat Rev 1993; 19:45–55

    Article  PubMed  CAS  Google Scholar 

  4. Cormier Y, Eisenhauer E, Muldal A, et al. Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer. A study of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 1994; 5: 283–5

    PubMed  CAS  Google Scholar 

  5. Abratt RP, Bezwoda WR, Falkson G, et al. Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. J Clin Oncol 1994 Aug; 12(8): 1535–40

    PubMed  CAS  Google Scholar 

  6. Lund B, Hansen OP, Theilade K, et al. Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 1994 Oct 19; 86(20): 1530–3

    Article  PubMed  CAS  Google Scholar 

  7. Catimel G, Vermorken JB, Clavel M, et al. A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of Che head and neck. Ann Oncol 1994; 5: 543–7

    PubMed  CAS  Google Scholar 

  8. Casper ES, Green MR, Kelsen DP, et al. Phase II trial of gemcitabine (2′,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 1994; 12: 29–34

    Article  PubMed  CAS  Google Scholar 

  9. Carmichael J, Fink U, Russell RCG, et al. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 1996; 73: 101–5

    Article  PubMed  CAS  Google Scholar 

  10. Sessa C, Aamdal S, Wolff I, et al. Gemcitabine in patients with advanced malignant melanoma or gastric cancer: Phase II studies of the EORTC Early Clinical Trials Group. Ann Oncol 1994; 5: 471–2

    PubMed  CAS  Google Scholar 

  11. Moore DF, Pazdur R, Daugherty K, et al. Phase II study of gemcitabine in advanced colorectal adenocarcinoma. Invest New Drugs 1992; 10: 323–5

    Article  PubMed  Google Scholar 

  12. Gemzar injection. Pharm J 1995 Dec 23/30; 255: 906

  13. Koch P, Johnson N, van Schaik J, et al. Gemcitabine: clinical and economic impact in inoperable non-small cell lung cancer. AntiCancer Drugs1995 Dec; 6 (Suppl. 6): 49–54

    Article  PubMed  CAS  Google Scholar 

  14. Lluch A, Pérez-Manga G, Garcia-Conde J, et al. Early phase II study of gemcitabine in combination with doxorubicin in advanced breast cancer [abstract]. Oncologia 1995; 18(6): 38

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Early experience with gemcitabine in solid tumours encouraging. Drugs Ther. Perspect 7, 5–7 (1996). https://doi.org/10.2165/00042310-199607110-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-199607110-00002

Search

Navigation